肿瘤细胞治疗研究
英文原题：SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia.
贝林妥欧单抗是一种靶向 CD19 的双特异性 T 细胞衔接抗体构建体，用于治疗表达 CD19 的 B 细胞恶性肿瘤。
SOHO前沿进展与待解问题｜治疗B细胞急性淋巴细胞白血病时，贝林妥欧单抗的最佳使用时机。贝林妥欧单抗是一种靶向CD19的双特异性T细胞衔接抗体构建体，用于治疗表达CD19的B细胞恶性肿瘤。多项成人和儿童B-ALL临床试验证明，贝林妥欧单抗对复发患者有效，对初始化疗后仍有残留病灶的患者也有效。该药安全性良好，适用于大多数患者。但仍有若干关键问题待解：在初始治疗阶段，贝林妥欧单抗能否替代标准化疗中毒性较大的部分；其能否作为造血干细胞移植的桥接治疗；以及既往使用贝林妥欧单抗是否会影响后续CAR-T细胞治疗效果。
Blinatumomab is a CD19 targeting bi-specific T-cell engager antibody construct developed for the treatment of CD19 expressing B-cell malignancies. Numerous adult and pediatric B-ALL clinical trials have demonstrated blinatumomab's efficacy in the relapse setting as well as in patients with residual disease after upfront chemotherapy. The safety profile of blinatumomab is also favorable, making it a feasible option for most patients. Several key questions remain, including the role of blinatumomab as a replacement for toxic elements of standard chemotherapy regimens in the upfront setting, its role as a bridge to hematopoietic stem cell transplantation, or whether previous blinatumomab impacts the efficacy of subsequent CAR-T cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
